Kommentar
Comparison of risankizumab with apremilast for the treatment of moderate psoriasis
British Journal of Dermatology · 2023
DOI: 10.1093/bjd/ljad349 ↗Kurz gefasst
Kommentar in der Zeitschrift British Journal of Dermatology, 2023. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Psoriasis.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Antibodies, MonoclonalPsoriasisHumansThalidomideSeverity of Illness IndexTreatment OutcomeDouble-Blind Method
Substanzen
risankizumabapremilastAntibodies, MonoclonalThalidomide
Zitieren
APA
(2023). Comparison of risankizumab with apremilast for the treatment of moderate psoriasis. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad349
Vancouver
Comparison of risankizumab with apremilast for the treatment of moderate psoriasis. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad349
BibTeX
@article{euvimed2023,
title = {Comparison of risankizumab with apremilast for the treatment of moderate psoriasis},
journal = {British Journal of Dermatology},
year = {2023},
doi = {10.1093/bjd/ljad349}
}
EUVIMED